Pfizer: meets primary endpoints in autoimmune disorder

(CercleFinance.com) - US pharma giant Pfizer has said that two experimental drugs treating an autoimmune disorder that results in hair loss have met their primary goals in a mid-stage trial.


In a Phase 2a study on oral Janus kinase (JAK) 3 inhibitor PF-06651600 and tyrosine kinase (TYK) 2/JAK1 inhibitor PF-06700841, a tyrosine kinase (TYK) 2/JAK1 inhibitor, met the primary efficacy endpoint in improving hair regrowth on the scalp relative to baseline after 24 weeks of treatment in patients with alopecia areata.

The data was presented during a session at the 27th European Academy of Dermatology and Venereology (EADV) congress in Paris.

Copyright (c) 2018 CercleFinance.com. All rights reserved.